Drug Development in Obesity

Back Bay’s monthly healthcare roundup covers drug development in obesity, including: 

  • A brief introduction to glucagon-like peptide 1 (GLP-1) agonists

  • Why GLP-1s’ popularity is skyrocketing as treatment for type 2 diabetes and obesity

  • How amylin and petrelintide (a long-acting amylin analogue) are being newly re-imagined for the obesity space, as well as muscle-targeted approaches like myostatin and activins

  • Where BD and investor interest lies as these drugs are expected to have north of $150B in sales annually within the next decade

  • What’s happening in early to late-stage drug development

  • What the future holds for this sector, possibly to include cannabinoid one receptor inverse agonists and mitochondrial targets for metabolic disease

LISTEN TO THE PODCAST

Back Bay Life Science Advisors